Komori
TAUNS Laboratories (197A) · RiskWorsened

Rising Interest Rates and Breaches of Financial Covenants

First written in FY2024. 6 of 7 entries say "Worsened", first in FY2025-H1. Latest entry: FY2026.

7entries
3years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024WorsenedFY2025-H1 – FY20262024: 120242025: 220252026: 42026
Same theme, other companies
Risk of Loss of Benefit of Time Due to Breach of Financial CovenantsA theme 291 companies write about · 295 as a headwind · 0 as a tailwind

TAUNS Laboratories moved to the "Worse" side of this theme in 2025, 2 years after the typical company in this theme (2023).

17 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 297 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「Outstanding borrowings: ¥10,162.109 million」

    In connection with construction of the new plant and other projects, outstanding borrowings under the syndicated loan increased from ¥6,945 million in the previous fiscal year to ¥10,162.109 million. The company stated that it was not in breach of any financial covenants.
  2. FY2026-H1WorsenedAnnual report

    「We have entered into a syndicated loan agreement with 4 relationship banks. The agreement and financial covenants are as follows: borrowings outstanding, ¥10,338 million.」

    Borrowings outstanding under the syndicated loan reached ¥10,338 million due to borrowings for construction of the new plant and other purposes. The company was not in breach of its financial covenants at the end of the interim accounting period.
  3. FY2025WorsenedAnnual report

    「During the fiscal year (from 1 July 2024 to 30 June 2025), we entered into a syndicated loan agreement with 4 relationship banks, with borrowings outstanding of ¥6,945 million.」

    Outstanding borrowings under the syndicated loan increased from ¥2,803 million in the previous fiscal year to ¥6,945 million, and long-term borrowings also increased. The company was not in breach of its financial covenants at the end of the fiscal year.
  4. FY2025-H1WorsenedAnnual report

    「Total liabilities increased by ¥4,126.829 million from the end of the previous fiscal year to ¥19,721.395 million. This was mainly due to an increase in long-term borrowings following the partial drawdown of a syndicated loan facility arranged with financial institutions to fund construction of the new plant. The company was not in breach of its financial covenants at the end of the interim accounting period.」

    The syndicated loan was partially drawn to fund construction of the new plant, increasing long-term borrowings from ¥4,307 million to ¥8,083 million. The company disclosed that it was not in breach of its financial covenants.
  5. FY2024First statedAnnual report

    「We recognize that interest-bearing debt is substantial relative to revenue. If market interest rates rise in the future, our borrowing rates are also expected to increase.」

    The financial covenants require the company to maintain net assets at 75% or more of the benchmark amount and not incur ordinary losses for 2 consecutive periods.
Moved together

"Impairment of Investment Securities and Other Assets Due to Impairment in the Value of Investees" moved the same way as this thread, in the same document, in 4 of its 7 moves.

4222★1234
  1. ★This thread
  2. 1Impairment of Investment Securities and Other Assets Due to Impairment in the Value of Investees4×
  3. 2Dependence on Sales of COVID-19-Related Products2×
  4. 3Dependence on Sales to Suzuken Group and Credit Risk2×
  5. 4Risk of operational interruption under a single-site structure centered on the Kamishima Plant2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet. It last moved in the General Meetings of Shareholders of 2026-09-02: "Worsened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Rising Interest Rates and Breaches of Financial Covenants | TAUNS Laboratories,Inc. (197A) | Komori